GLP-1之后,诺和诺德的“诺亚方舟”在哪里?

药时代
27 May

正如特斯拉以Model 3颠覆汽车工业的逻辑,却不得不用Cybertruck证明自己仍是创新先锋,诺和诺德——这家以司美格鲁肽重塑代谢治疗规则的百年药企——正站在相似的十字路口。GLP-1药物的“减重奇迹”被礼来的多靶点疗法全面压制,新收获的“药王”光环在竞争与围剿中褪色,属于司美格鲁肽的“胰岛素式传奇”也接近尾声。医药行业的残酷在于,新故事的试错成本远超想象,每一次临床失败都可能引发市值雪崩。没...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10